$93 million. That's what Memento Medicines raised before it had a single clinical data point. The bet is on a mechanism, not data.
The lead program, MMT-205, targets neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), two markets worth billions annually where anti-VEGF monotherapies have dominated for nearly two decades.
IND-enabling studies are underway; clinical trials are expected to begin in 2027.
Why Tie2 matters
Every approved treatment for wet AMD and DME works the same way: block VEGF. Eylea, Lucentis, Vabysmo — all are anti-VEGF agents that stop abnormal blood vessel growth and leakage. They work, but they only address half the pathology.
The other half is vascular stability.
Tie2 is a receptor that maintains the integrity of blood vessels in the retina. When it's active, vessels stay sealed and healthy. When it's not, they leak — even if VEGF is suppressed. MMT-205 is designed to do both: activate Tie2 while inhibiting VEGF, in a single molecule.
"MMT-205 holds the potential to become a best-in-class biologic therapy in nAMD and DME," said Naveen Daryani, CEO of Memento Medicines.
In preclinical models, the bispecific produced greater Tie2 activation and improved retinal vasculature integrity compared to current therapies, according to data the company presented alongside the financing announcement.
Memento Medicines — launch financing
The round included Sanofi Ventures and Samsara BioCapital alongside existing backers. Proceeds fund IND-enabling studies for MMT-205 through 2027. · GlobeNewswire, June 2026
The Sera Medicines model
Memento is the fifth company to emerge from Sera Medicines, an antibody accelerator RA Capital launched in 2023. The structure is deliberate: find a licensed asset with validated mechanism data, build a company around it, syndicate the round with specialist investors, and push toward clinical proof-of-concept before the next financing.
The model has precedents. Sera Medicines' earlier subsidiaries include Sera Therapeutics (oncology bispecifics) and Sera Immunology (autoimmune antibodies). None have reached the market yet, but the accelerator approach reduces the risk of building from scratch — each company starts with a licensed molecule rather than a discovery platform.
For RA Capital, the economics are straightforward. A $93M Series A is large for a single-asset company, but the syndicate shares risk. If MMT-205 succeeds, the return multiples are in pharma acquisition territory. If it fails, the loss is contained to one subsidiary and one asset.
A syndicate built for ophthalmology
The investor group is notable for its concentration of ophthalmology expertise. Forbion has backed multiple retinal therapy companies; RA Capital's Sera Medicines accelerator, which founded Memento, was purpose-built for antibody therapeutics. Avego BioScience Capital and Sanofi Ventures add development-stage and strategic depth.
"Given Forbion's experience in building and guiding ophthalmology companies, partnering with Memento allows MMT-205 to reach its full potential," said Dmitrij Hristodorov, General Partner at Forbion.
Memento is the fifth subsidiary to emerge from Sera Medicines, an antibody accelerator formed in 2023. The model — create a company around a licensed asset, fund it through a syndicate, and push toward proof-of-concept — mirrors what RA Capital has done successfully in earlier biotech cycles.
The competitive landscape
Anti-VEGF monotherapies generated more than $12 billion in combined sales in 2025. Regeneron's Eylea, Roche's Vabysmo, and Bayer's aflibercept biosimilars dominate the space. The question is whether a dual-mechanism therapy can unseat them.
Vabysmo (faricimab), approved in 2022, was the first bispecific antibody for retinal disease — it blocks both VEGF-A and Ang-2. MMT-205 takes a different approach: activating Tie2 rather than blocking Ang-2. The difference is mechanistic. Blocking Ang-2 removes a brake on Tie2 signaling. Activating Tie2 directly may produce a stronger signal.
Preclinical comparisons have not been published head-to-head, but the company claims "greater Tie2 activation" than existing approaches. The clinical data — when it arrives — will settle the question.
The retinal disease market rewards differentiation. Patients with nAMD require injections every four to eight weeks for life. A therapy that extends that interval to three or four months would capture significant share regardless of the mechanism. That is the prize MMT-205 is aiming for.
What happens to the retinal therapy market a year from now?
Probability: 60% — preclinical Tie2 engagement data is robust, but the nAMD and DME trial landscape is littered with mechanisms that worked in animals and failed in humans.
✅ Arguments for
+ The Sera Medicines model has de-risked earlier antibody programs through disciplined asset selection
+ $93M is sufficient for IND-enabling studies and Phase 1, reducing near-term financing risk
Confirmation criteria: IND clearance in Q1 2027 with no clinical hold
❌ Arguments against
− Vabysmo already holds the bispecific retinal therapy market with growing real-world evidence
− Clinical trials for nAMD and DME are slow and expensive; a single Phase 2 can consume $50M+ and 3 years
Disconfirmation criteria: any safety signal in IND-enabling toxicology that delays or blocks the filing
IND filing status and FDA response, Q1–Q2 2027
Phase 1 tolerability data in healthy volunteers, H2 2027
Tie2 engagement biomarkers vs. baseline in early cohorts
Partnership or acquisition interest from Regeneron or Roche by 2028
Development scenarios
🟢 Optimistic scenario (20%)
Implications: The bispecific dual-mechanism approach becomes the new standard for retinal care, and MMT-205 leapfrogs Vabysmo on durability.
🟡 Base-case scenario (60%)
Implications: Memento remains independent through Phase 2. The Tie2 mechanism is validated but differentiation vs. Vabysmo is modest.
🔴 Pessimistic scenario (20%)
Implications: The dual-mechanism approach in ophthalmology narrows to Ang-2/VEGF bispecifics only, leaving Vabysmo's class unchallenged.